ProKidney Corp. filings document a late clinical-stage biotechnology issuer focused on rilparencel, an autologous renal cell therapy candidate for chronic kidney disease in patients with diabetes. Recent Form 8-K reports furnish operating and financial results, Regulation FD investor presentations, clinical-study and development-plan updates, FDA-pathway disclosures, financial-position information, and material-event or material-agreement disclosures.
Proxy materials describe annual meeting proposals, board elections, auditor ratification, stockholder voting procedures, and governance matters for the public company.
Form 144
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
515.00%
Tags
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
515.00%
Tags
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
515.00%
Tags
-
S-8 POS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
S-8 POS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
S-8 POS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
S-8 POS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
-
POS AM
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.82%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.54%
Tags
FAQ
How many PROKIDNEY (PROK) SEC filings are available on StockTitan?
StockTitan tracks 60 SEC filings for PROKIDNEY (PROK), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for PROKIDNEY (PROK)?
The most recent SEC filing for PROKIDNEY (PROK) was filed on July 8, 2025.